NASDAQ:MBIO
Mustang Bio Inc Stock News
$0.293
+0.0329 (+12.65%)
At Close: May 02, 2024
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
08:15am, Thursday, 07'th Sep 2023
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs i
Mustang Bio to Participate in Two August 2023 Investor Conferences
08:00am, Thursday, 03'rd Aug 2023
WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
03:04pm, Tuesday, 13'th Jun 2023
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
10:58am, Monday, 12'th Jun 2023
The consensus price target hints at a 331.2% upside potential for Mustang Bio, Inc. (MBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
11:05am, Friday, 26'th May 2023
The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
Mustang Bio: This Horse May Gallop Still
04:55pm, Friday, 23'rd Sep 2022
We are circling back on small CAR-T developmental firm Mustang Bio, Inc. today for the first time in nearly a year and a half. The stock has been under pressure since we last looked in on this story,
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
08:00am, Thursday, 08'th Sep 2022
WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs i
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
01:55pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Mustang Bio, Inc. (MBIO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
08:05pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrough
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
09:29am, Wednesday, 27'th Jul 2022 Benzinga
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Pag
What to Know About Buying Penny Stocks on June 23rd
11:00am, Thursday, 23'rd Jun 2022 PennyStocks
Here's what you need to know about trading penny stocks on June 23rd
The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | P
What to Know About Buying Penny Stocks on June 23rd
07:00am, Thursday, 23'rd Jun 2022
Here's what you need to know about trading penny stocks on June 23rd The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | P
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
03:28pm, Thursday, 19'th May 2022
Mustang Bio Inc (NASDAQ: MBIO) announced interim data from the Phase 1/2 trial of MB-107, lentiviral gene therapy for X-linked severe combined immunodeficiency (X-SCID), also known as bubble boy di
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
12:45pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation
Caribou Charges Ahead on Study Results
03:07pm, Tuesday, 17'th May 2022
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the prese